US Patent

US11345677 — Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same

Method of Use · Assigned to Servier Pharmaceuticals LLC · Expires 2039-01-16 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects solid forms of a compound used to treat cancer, as well as pharmaceutical compositions and methods of treatment involving those solid forms.

USPTO Abstract

Provided are solid forms of a compound useful for treating cancer, pharmaceutical compositions thereof, and methods of treating cancer comprising administering the solid forms described herein to a patient in need thereof.

Drugs covered by this patent

Voranigo (VORASIDENIB) · Servier

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3978`	—	Voranigo
`U-3978`	—	Voranigo

Patent Metadata

Patent number: US11345677
Jurisdiction: US
Classification: Method of Use
Expires: 2039-01-16
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Servier Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.